- Report
- September 2022
- 300 Pages
China
From €2672EUR$3,000USD£2,330GBP
- Report
- June 2022
- 1500 Pages
Global
From €3473EUR$3,900USD£3,029GBP
- Report
- February 2022
- 360 Pages
United States
From €3206EUR$3,600USD£2,796GBP
- Report
- October 2021
- 78 Pages
Global
From €712EUR$800USD£621GBP
- Report
- September 2024
- 156 Pages
Global
From €4141EUR$4,650USD£3,611GBP
- Report
- May 2025
- 170 Pages
Global
From €4141EUR$4,650USD£3,611GBP
- Report
- April 2025
- 162 Pages
Global
From €4141EUR$4,650USD£3,611GBP
- Report
- August 2023
- 175 Pages
Global
From €5299EUR$5,950USD£4,621GBP
- Report
- June 2023
- 120 Pages
Global
From €5299EUR$5,950USD£4,621GBP
- Report
- December 2023
- 137 Pages
Global
From €2204EUR$2,475USD£1,922GBP
€4408EUR$4,950USD£3,844GBP
- Report
- May 2024
- 90 Pages
United States
From €3518EUR$3,950USD£3,067GBP
- Report
- January 2024
- 200 Pages
Global
From €3696EUR$4,150USD£3,223GBP
- Report
- July 2023
- 145 Pages
Global
From €2805EUR$3,150USD£2,446GBP
- Report
- January 2024
- 200 Pages
Global
From €3696EUR$4,150USD£3,223GBP
- Report
- June 2024
Global
From €4408EUR$4,950USD£3,844GBP
- Report
- February 2024
- 75 Pages
Global
From €4408EUR$4,950USD£3,844GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1781EUR$2,000USD£1,553GBP
- Clinical Trials
- April 2025
- 550 Pages
Global
From €4453EUR$5,000USD£3,883GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2672EUR$3,000USD£2,330GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1781EUR$2,000USD£1,553GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more